Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 11:58   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this

  Be the first to like this.
 


 

4869  2102  487  709 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 189.60+1.13 
 VXX 36.69-1.89 
 BAC 16.235+0.025 
 AAPL 99.20+1.53 
 XLF 22.405+0.085 
 EEM 40.755+0.035 
 IBIO 2.62-0.59 
 PFE 27.828-0.002 
 FB 76.83+0.88 
 QQQ 93.93+0.93 
Partners & Brokers